.jpg?format=webp&quality=80&width=3840)
The objective of this study was to use the National Cancer Database to characterize clinical factors associated with esthesioneuroblastoma treatment delays and the impact of these delays on overall survival. The investigation subsequently found that delays during and prolongation of radiotherapy for esthesioneuroblastoma appear to be associated with decreased survival. A significant association was identified between increased regional radiation dose above 66 Gy and decreased DTI (OR = 0.54, 95% CI 0.35–0.83, p = 0.01) and increased RTD (OR = 3.94, 95% CI 2.36–6.58, p < 0.001) durations. Therefore, delays during and prolongation of radiotherapy for esthesioneuroblastoma appear to be associated with decreased survival.
Like
Save
Share